Center for Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Dr. Bohr-Gasse 9, 1030 Vienna, Austria.
Mass Spectrometry Facility, Max Perutz Labs, Dr. Bohr-Gasse 9, 1030 Vienna, Austria.
Cell Rep. 2020 Mar 3;30(9):3171-3182.e6. doi: 10.1016/j.celrep.2020.02.035.
Protein phosphatase 2A (PP2A) is an important regulator of signal transduction pathways and a tumor suppressor. Phosphorylation of the PP2A catalytic subunit (PP2A) at tyrosine 307 has been claimed to inactivate PP2A and was examined in more than 180 studies using commercial antibodies, but this modification was never identified using mass spectrometry. Here we show that the most cited pTyr monoclonal antibodies, E155 and F-8, are not specific for phosphorylated Tyr but instead are hampered by PP2A methylation at leucine 309 or phosphorylation at threonine 304. Other pTyr antibodies are sensitive to PP2A methylation as well, and some cross-react with pTyr residues in general, including phosphorylated hemagglutinin tags. We identify pTyr using targeted mass spectrometry after transient overexpression of PP2A and Src kinase. Yet under such conditions, none of the tested antibodies show exclusive pTyr specificity. Thus, data generated using these antibodies need to be revisited, and the mechanism of PP2A inactivation needs to be redefined.
蛋白磷酸酶 2A(PP2A)是信号转导途径的重要调节剂和肿瘤抑制因子。已经声称 PP2A 催化亚基(PP2A)在酪氨酸 307 处的磷酸化会使 PP2A 失活,并使用商业抗体在超过 180 项研究中进行了检查,但从未使用质谱法鉴定出这种修饰。在这里,我们表明最常被引用的 pTyr 单克隆抗体 E155 和 F-8 不是特异性地针对磷酸化的 Tyr,而是受到 PP2A 在亮氨酸 309 处的甲基化或在苏氨酸 304 处的磷酸化的阻碍。其他 pTyr 抗体也对 PP2A 甲基化敏感,并且一些抗体与一般的 pTyr 残基交叉反应,包括磷酸化的血凝素标签。我们在瞬时过表达 PP2A 和Src 激酶后使用靶向质谱法鉴定 pTyr。然而,在这种情况下,没有一种测试抗体显示出 pTyr 的特异性。因此,需要重新检查使用这些抗体生成的数据,并且需要重新定义 PP2A 失活的机制。